Navigation Links
Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study

Most Patients Achieved at Least 75 Percent Improvement in Psoriasis Signs and Symptoms at Week 12; in Four of Five Dosing Groups, More Than Half Achieved 90 Percent Improvement

ABBOTT PARK, Ill., May 04, 2007 /PRNewswire-FirstCall/ -- New Phase II study results show Abbott's investigational treatment, ABT-874, reduced psoriasis symptoms significantly in the majority of patients treated. At 12 weeks, nine out of 10 patients with moderate to severe psoriasis achieved 75 percent improvement in psoriasis signs and symptoms in four of the five dosing groups receiving ABT-874, versus 3 percent of patients receiving placebo. Also, more than half of patients achieved 90 percent improvement, in the same four of five ABT-874 dosing groups, versus 0 percent of those receiving placebo. The results will be presented next week at the Society for Investigative Dermatology annual meeting in Los Angeles. ABT-874 is a fully human monoclonal antibody designed to target and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation in psoriasis and other autoimmune disorders.

ABT-874 represents a novel approach to treating psoriasis, targeting a part of the inflammatory response that is not addressed by any therapy available today. Abbott's biologic drugs in development, including ABT-874, are designed to selectively inhibit proteins that are responsible for inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Abbott plans to begin Phase III psoriasis studies with ABT-874 later this year.

"These early results are promising and warrant further development of ABT-874 as an additional treatment option for moderate to severe psoriasis patients," said Kenneth Gordon, M.D., associate professor of dermatology, Northwestern University, Feinberg School of Medicine, head, Division of Dermatology, Evanston Northwestern Healthcare, and study investigator. "There is a s
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
3. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
8. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
11. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Post Your Comments:
(Date:7/24/2014)... July 24, 2014 Consolidated Net Profit increased ... Highlights   , India Business grew by 20.87% ... to Rs. 4,886.70 Mn Rest of World (ROW) Business ... Business grew by 34.53% to Rs. 977.26 Mn Latin ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
(Date:7/24/2014)... Scotland , July 24, 2014 Cancer patients ... gain access to state-of-the-art cancer treatment closer to home when ... next year. Varian Medical Systems (NYSE: VAR ... an order was placed in June for four TrueBeam™ medical ... systems, which offer fast and efficient radiotherapy and radiosurgery treatments, ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
(Date:7/24/2014)... CO (PRWEB) July 24, 2014 This year ... by E Light Electric and Jackson National Life, will be ... begins at 7 am, the Kids Fun Run at 7:50 ... Walk starts at 9 a.m. , “The Walk to End ... strength and dedication in the fight against this devastating disease, ...
(Date:7/24/2014)... like a medical device or surgical implant is put ... to Northwestern University,s Guillermo Ameer, most of the time, ... function. , "You will always get an inflammatory response ... in Northwestern,s McCormick School of Engineering and Applied Science ... Medicine. "A problem with commonly used plastic materials, in ...
(Date:7/24/2014)... Children,s Hospital and the University of Tennessee Health Science ... new drug shown to safely reduce the viral load ... with respiratory syncytial virus (RSV). RSV is the most ... children in the United States and worldwide. , ... Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab has ...
(Date:7/24/2014)... Atlanta, GA (PRWEB) July 24, 2014 ... Act on Tuesday, President Obama cited the Atlanta ... 35 model programs from across the country ( ... training as an essential pillar of U.S. economic ... replicated nationally. , “This recognition from President Obama ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Antioxidant biomaterial promotes healing 2Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... Reporter , MONDAY, Sept. 27 (HealthDay News) -- There ... other noncarbonated beverages are associated with physical activity they ... In a study of more than 15,000 middle and ... who drank sugar-sweetened beverages, including sports drinks, were more ...
... Nearly 500 researchers, clinicians and mental health advocates ... Conference, Perinatal Mental Health Research: Harvesting the Potential, Oct. ... in Pittsburgh. The event, which focuses on women,s mental ... former First Lady Rosalynn Carter, who has been an ...
... Reinberg HealthDay Reporter , SATURDAY, Sept. 25 ... not drinking as much water as they should, and ... suggests. "Even mild dehydration can affect physiological function, ... said Samantha Heller, clinical nutrition coordinator at the Center ...
... to arrest the growth and spread of tumors, there have ... internal instruction manual. In a new study, a team ... molecule able to prevent cancer genes from "hearing" those instructions, ... published online by the journal Nature , demonstrates that ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... about heart risks, U.S. health officials on Thursday severely ... patients with type 2 diabetes who cannot control their ... Administration officials also ordered the drug,s manufacturer, GlaxoSmithKline, to ...
... and GLG Pharma, LLC announced today that they have ... LLC has acquired the exclusive worldwide rights to a ... Researchers at Moffitt discovered several classes of STAT3 ... drugs. "Persistently activated STAT3 is a major ...
Cached Medicine News:Health News:Study Finds Teens Think Sports Drinks Are Healthy 2Health News:Study Finds Teens Think Sports Drinks Are Healthy 3Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 2Health News:Researchers create first molecule blocks key component of cancer genes' on-off switch 3Health News:FDA Restricts Access to Avandia 2Health News:FDA Restricts Access to Avandia 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... glucose monitor elevates bedside glucose testing to ... approaches the quality of central laboratory testing. ... measuring strip technology. Current glucose strips ... Multi-Well system measures and corrects hematocrit interference ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Medicine Products: